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Introduction: The acute GVHD grading for the Center for
International Blood and Marrow Transplant Research
(CIBMTR) reporting is based on criteria published by
Przepiorka et al (Bone Marrow Transplant,1995;15:825).
While the CIBMTR’s FormsNet3SM application allows elec-
tronic data submission, data professionals still need to
manually assign organ stages and overall grade, and track
data over time. We report the design and validation of an
electronic grader tool to automate acute GVHD severity
scoring.
Methods: Tables from the Przepiorka et al and the Rowlings
et al (Br J Haematol 1997; 97: 855) papers were used to build
logic for the “Consensus” and the IBMTR grading schemata
respectively. This free tool, aGVHD Grader (agvhd.com), was
developed using HTML, CSS and JavaScript. We also
reviewed the acute GVHD data on the NMDP and CIBMTR
forms for 30 patients with severe acute GVHD and tested
data entry in a prototype database version of the aGVHD
Grader.
Results: The 30 randomly selected allo-BMT patients were
transplanted between 1999 and 2014 with median age of
116.1 y and average follow-up of 2.33 y. Maximal acute
GVHD overall grade on submitted forms was recorded as II
in 2 (6.6%), III in 13 (43.3%) and IV in 15 (50%) cases. On this
retrospective review, the maximal grade was concordant in
22 cases but was revised from IV to III in eight cases; these
eight cases were scored based on institutional practice of
assigning stage 4 lower GI as overall grade IV. Additional
cause for diarrhea and elevated bilirubin was considered in
22 (73%) cases and downstaging done in 18 of them.
CIBMTR forms do not record downstaging and we wereFigure 1unable to ﬁnd consistent documentation of downstaging
process in the scorer’s internal data records. Histologic
evidence of GVHD in stomach or duodenum was found in
19 out of 21 cases with upper GI endoscopy; 11 of these
were scored as upper GI involved and 10 as not involved,
clinically.
We entered clinical data and bilirubin values into the
aGVHD Grader which automatically assigned organ stage,
downstaged for additional cause, and derived maximal
Consensus overall grade and IBMTR severity score accurately
in 100% cases when compared with manual scores using the
published criteria. We also generated a sample one-screen
view of daily acute GVHD assessments using the prototype
database version of the Grader (Figure 1).
Conclusions: Acute GVHD is a clinical syndrome with
considerable within-grade heterogeneity with different
patterns of skin, liver or gut involvement. Data professionals
commonly face situations when there is ambiguity in scoring
and in judging GVHD severity. The software program re-
ported here automates the organ staging and grading of
acute GVHD and enables tracking change over time. This may
help with consistency in data capture and error reduction
and serve as a useful record for outcomes reporting and
clinical research.120
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Background: Time management and cost reduction is in
the forefront for many centers today. Centers need to save
time and money, while accurately reporting data to the
Center for International Bone Marrow Transplant Research
(CIBMTR). Our center has researched and taken steps to
address these issues. As a result, our process for.
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made more efﬁcient.
Rationale: We examined our internal form auditing pro-
cesses as part of a cost reduction measure. Previously, we
were auditing 100% of all research and Transplant Essential
Data (TED) forms. Because of experienced data managers
and their continued training, our error rate was low
enough that reducing the breadth of the audit was
justiﬁed.
Best Practices: Most events occur in the ﬁrst year after
transplant. Therefore, we placed importance on this time
frame and varied the levels of importance on other forms
and used stratiﬁed sample auditing to cover them. This
allowed us to notice any trends in errors and provide
training. By selecting a percentage of all forms, we can
efﬁciently give feedback to data managers and provide
targeted training sessions.
Method:We are currently auditing 100% of research; post-
TEDs through 1 year. After 1 year we are utilizing the
stratiﬁed sample method for auditing post TEDs 2-6 years
at 50% and over 6 years at 25% per data manager. A data
manager may request a form be audited at any time point.
New employees are audited at 100% for their ﬁrst year.
We do routine education based on errors found on our
audits.
Outcome:We tracked our error rate over the past year and a
half and our calculated error rate was low enough to warrant
this change. Our current average error rate was 0.41 errors
per form. Through tracking audited forms, we found that we
saved 2.7 weeks or 107.3 hours per year of the auditor’s time.
Revising the auditing process has improved time, efﬁciency
and lowered the cost of auditing, while maintaining high
quality work with low error rates. The time saving of
approximately 3 weeks can be utilized in opening more
studies and other projects data coordinators are responsible
for.
Future: In phase two of time management, we have
streamlined our submission processes for auditing and
saving versions of forms. FormsNet3 (FN3) has proven that
we no longer need to do this and will in turn save valuable
drive space. The amount of time used to convert the form to
PDF, submit it, and correcting and resaving will also be saved
with the new process. We utilize the audit sheet to track
errors, communicate to datamanagers, andmake corrections
in FN3 e all without having to PDF a form. Additionally, er-
rors are sent and seen on a weekly basis and data managers
are given a week to make the corrections inFN3. We found
3.8 weeks per year of data managers’ time can be saved with
this change in process.BMT ADMINISTRATION/QUALITYFigure. BMT Readmission Rates - All Transplants.121
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indicator of poor quality care, are costly and largely pre-
ventable. As the focus of hospital readmissions becamemore
evident with the Affordable Care Act, our program began
discussions on how to reduce our 30 day readmission rate.
Since BMT programs are structured, process driven, and well
communicated, we felt this combination was ideal for iden-
tiﬁcation of weaknesses and areas for improvement to
reduce our rate.
Implementations: Our ﬁrst action was a real time multi-
disciplinary review of every 30 day readmission. The hope
was to identify contributing factors with input from all team
members that may not have been captured through docu-
mentation alone. Unfortunately no common themes were
identiﬁed. Other early on initiatives included:
 A hospital wide initiative was instituted for Nurse on
Call to contact all patients by phone within 48 hours of
discharge.
 We began utilizing our BMT PharmDs for allogeneic
discharge medication education. Unit nurses and nurse
coordinators still perform medication education; add-
ing the third clinician to create the individualized
medication schedule was a hope for increasing medi-
cation compliance.
 Our nurses began assessing autologous patients in
person within 48-72 hours of discharge instead of im-
mediate return to their local oncologist.
 All patients must be seen by a BMT physician within 5
days of discharge and have the appointment scheduled
prior to leaving the hospital.
 A longstanding effort is the post-transplant preparation
groupheldmonthlyprior todischarge.Multi-disciplinary
teammembersgather toeducatepatients and families on
what to expect after discharge.
A revived effort in reducing readmission was warranted
as the pressure to decrease our rate continued. The most
recent initiatives this year include:
 The creation of a same day BMT Acute Care Clinic. If
patients call with complaints, there are dedicated ap-
pointments where BMT physicians assess and treat
patients the same day.
 Midlevel providers and transplant nurse coordinators
began a twice a week huddle to discuss upcoming
discharges and identify potential hurdles to discharge.
 Mid-level providers began collecting a readmission
survey in attempt to gather more data surrounding the
